Cited by 653Cancer-related Molecular PathwaysUbiquitin and proteasome pathwaysHeat shock proteins research

The DOI matches its Crossref record; 134 of the 144 references it cites were found in a registry or an index.

MDM2 — master regulator of the p53 tumor suppressor protein

Momand, Jamil, Wu, Hsiao-Huei, Dasgupta, Gargi·2000·Gene

Open this paper in CoChat — free account

Abstract

MDM2 is an oncogene that mainly functions to modulate p53 tumor suppressor activity. In normal cells the MDM2 protein binds to the p53 protein and maintains p53 at low levels by increasing its susceptibility to proteolysis by the 26S proteosome. Immediately after the application of cellular stress, the ability of MDM2 to bind to p53 is blocked or altered in a fashion that prevents MDM2-mediated degradation. As a result, p53 levels rise, causing cell cycle arrest or apoptosis. In this review, we present evidence for the existence of three highly conserved regions (CRs) shared by MDM2 proteins and MDMX proteins of different species. These highly conserved regions encompass residues 42-94 (CR1), 301-329 (CR2), and 444-483 (CR3) on human MDM2. These three domains are respectively important for binding p53, for binding the retinoblastoma protein, and for transferring ubiquitin to p53. This review discusses the major milestones uncovered in MDM2 research during the past 12 years and potential uses of this knowledge in the fight against cancer.

Integrity signals

Registry

Crossref · 10.1016/s0378-1119(99)00487-4

Cites

134 of 134 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

THE UBIQUITIN SYSTEM
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Self-citation

Show all 144 references

Sorted by citations

Items 201–300 of 653

Radiosensitization by Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in in Vitro and in Vivo Human Cancer Models
Zhang, Z., Wang, H., Prasad, G., Li, M., Yu, D. S., Bonner, J. A., Agrawal, S., & Zhang, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0245-03 · Cited by 54
ATM dependent apoptosis in the nervous system
Lee, Y., & McKinnon, P. J. (2000) · APOPTOSIS · doi:10.1023/a:1009637512917 · Cited by 53
Signaling Intricacies Take Center Stage in Cancer Cells
Kumar, R., & Hung, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0189 · Cited by 54
Suppression of Src/ERK and GSK-3/β-catenin signaling by pinosylvin inhibits the growth of human colorectal cancer cells
Park, E., Chung, H., Park, H. J., Kim, G. D., Ahn, Y., & Lee, S. K. (2013) · Food and Chemical Toxicology · doi:10.1016/j.fct.2013.01.007 · Cited by 53
New frontiers in the treatment of liposarcoma, a therapeutically resistant malignant cohort
Hoffman, A., Lazar, A. J., Pollock, R. E., & Lev, D. C. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.11.001 · Cited by 52
Influence of zinc deficiency on Akt-Mdm2-p53 and Akt-p21 signaling axes in normal and malignant human prostate cells
Han, T., Schoene, N. W., & Lei, K. Y. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00042.2009 · Cited by 53
Design Principles Involving Protein Disorder Facilitate Specific Substrate Selection and Degradation by the Ubiquitin-Proteasome System
Guharoy, M., Bhowmick, P., & Tompa, P. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.692665 · Cited by 54
Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo
Hoffman-Luca, C. G., Ziazadeh, D., McEachern, D., Zhao, Y., Sun, W., Debussche, L., & Wang, S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2506 · Cited by 52
Gene interaction enrichment and network analysis to identify dysregulated pathways and their interactions in complex diseases
Liu, Y., Koyutürk, M., Barnholtz‐Sloan, J. S., & Chance, M. R. (2012) · BMC Systems Biology · doi:10.1186/1752-0509-6-65 · Cited by 52
Downregulation of wild-type p53 protein by HER-2/neu mediated PI3K pathway activation in human breast cancer cells: its effect on cell proliferation and implication for therapy
Li, Z., Ren, J., Li, H., Zhao Lu, K. O. N. G., & Zhu, H. (2004) · Cell Research · doi:10.1038/sj.cr.7290253 · Cited by 52
Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma
Uchida, Τ., Gao, J.-P., Wang, C., Jiang, S. X., Muramoto, M., Satoh, T., Minei, S., Shimura, S., Irie, A., Kameya, T., et al. (2002) · Urology · doi:10.1016/s0090-4295(01)01601-6 · Cited by 51
The SCFFSN-1 ubiquitin ligase controls germline apoptosis through CEP-1/p53 in C. elegans
Gao, M. X., Liao, E. H., Yu, B., Wang, Y., Zhen, M., & Derry, W. B. (2008) · Cell Death and Differentiation · doi:10.1038/cdd.2008.30 · Cited by 50
Polymorphisms of p16, p27, p73, and MDM2 Modulate Response and Survival of Pancreatic Cancer Patients Treated with Preoperative Chemoradiation
Chen, J., Li, D., Killary, A. M., Sen, S., Amos, C. I., Evans, D. B., Abbruzzese, J. L., & Frazier, M. L. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0220-8 · Cited by 50
Genetic transformation of lignin degrading fungi facilitated by Agrobacterium tumefaciens
Sharma, K. K., & Kuhad, R. C. (2010) · BMC Biotechnology · doi:10.1186/1472-6750-10-67 · Cited by 50
Mutant p53 proteins: Between loss and gain of function
Strano, S., Dell’Orso, S., Mongiovi, A. M., Monti, O., Lapi, E., Agostino, S. D., Fontemaggi, G., & Blandino, G. (2006) · Head & Neck · doi:10.1002/hed.20531 · Cited by 50
Chemosensitization and Radiosensitization of Human Cancer by Antisense Anti‐MDM2 Oligonucleotides
Wang, H., Oliver, P. G., Zhang, Z., Agrawal, S., & Zhang, R. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1281.025 · Cited by 50
Fluorescence polarization assay and inhibitor design for MDM2/p53 interaction
Zhang, R., Mayhood, T., Lipari, P., Wang, Y., Durkin, J., Syto, R., Gesell, J. J., McNemar, C., & Windsor, W. T. (2004) · Analytical Biochemistry · doi:10.1016/j.ab.2004.03.009 · Cited by 75
Complex dynamics of transcription regulation
Stavreva, D. A., Varticovski, L., & Hager, G. L. (2012) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2012.03.004 · Cited by 53
Nutlins and Ionizing Radiation in Cancer Therapy
Impicciatore, G. G., Sancilio, S., Miscia, S., & Pietro, R. D. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791033932 · Cited by 50
p53-Autophagy-Metastasis Link
Denisenko, T. V., Pivnyuk, A. D., & Zhivotovsky, B. (2018) · Cancers · doi:10.3390/cancers10050148 · Cited by 51
TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation
George, B., Kantarjian, H. M., Baran, N., Krocker, J. D., & Rios, A. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910782 · Cited by 53
Differential Gene Expression Profile between PC-14 Cells Treated with Free Cisplatin and Cisplatin-Incorporated Polymeric Micelles
Nishiyama, N., Koizumi, F., Okazaki, S., Matsumura, Y., Nishio, K., & Kataoka, K. (2003) · Bioconjugate Chemistry · doi:10.1021/bc025555t · Cited by 49
Manganese superoxide dismutase versus p53: the mitochondrial center
Holley, A. K., Dhar, S. K., & Clair, D. K. S. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05612.x · Cited by 49
Role of Xenobiotic Metabolic Enzymes in Cancer Epidemiology
Singh, M. S., & Michael, M. (2008) · Methods in molecular biology · doi:10.1007/978-1-60327-492-0_10 · Cited by 46
2,3′-Bis(1′H-indole) heterocycles: New p53/MDM2/MDMX antagonists
Neochoritis, C. G., Wang, K., Estrada‐Ortiz, N., Herdtweck, E., Kubica, K., Twarda‐Clapa, A., Żak, K. M., Holak, T. A., & Dömling, A. S. S. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.11.019 · Cited by 46
Olive Oil Polyphenol Oleuropein Inhibits Smooth Muscle Cell Proliferation
Abe, R., Beckett, J. S., Abe, R., Nixon, A. M., Rochier, A. L., Yamashita, N., & Sumpio, B. E. (2011) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2010.12.021 · Cited by 45
Quantitative shape analysis of chemoresistant colon cancer cells: Correlation between morphotype and phenotype
Pasqualato, A., Palombo, A., Cucina, A., Mariggiò, M. A., Galli, L., Passaro, D., Dinicola, S., Proietti, S., D’Anselmi, F., Coluccia, P., et al. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.01.022 · Cited by 45
Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain
Qian, Y., Hua, E., Bisht, K. S., Woditschka, S., Skordos, K. W., Liewehr, D. J., Steinberg, S. M., Brogi, E., Akram, M. M., Killian, J. K., et al. (2011) · Clinical & Experimental Metastasis · doi:10.1007/s10585-011-9421-9 · Cited by 45
Apoptosis-mediated inhibition of human breast cancer cell proliferation by lemon citrus extract.
Alshatwi, A. A., Shafi, G., Hasan, T. N., Al‐Hazzani, A. A., Alsaif, M. A., Alfawaz, M. A., Lei, K. Y., & Munshi, A. (2011) · PubMed · Cited by 46
Function and dysfunction of the human oncoprotein MDM2
Deb, S. P. (2002) · Frontiers in bioscience · doi:10.2741/a723 · Cited by 45
Dissociation Process of a MDM2/p53 Complex Investigated by Parallel Cascade Selection Molecular Dynamics and the Markov State Model
Tran, D. P., & Kitao, A. (2019) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.8b10309 · Cited by 46
Downregulation of MDM2 stabilizes p53 by inhibiting p53 ubiquitination in response to specific alkylating agents
Inoue, T. M., Geyer, R. K., Yu, Z. K., & Maki, C. G. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02123-8 · Cited by 43
MDM2 can interact with the C-terminus of AID but it is inessential for antibody diversification in DT40 B cells
MacDuff, D. A., Neuberger, M. S., & Harris, R. S. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2005.07.024 · Cited by 43
A Novel Functional Polymorphism C1797G in the MDM2 Promoter Is Associated with Risk of Bladder Cancer in a Chinese Population
Wang, M., Zhang, Z., Zhu, H., Fu, G., Wang, S., Wu, D., Zhou, J., Wei, Q., & Zhang, Z. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5155 · Cited by 43
FGF1 inhibits p53-dependent apoptosis and cell cycle arrest via an intracrine pathway
Bouleau, S., Grimal, H., Rincheval, V., Godefroy, N., Mignotte, B., Vayssière, J., & Renaud, F. (2005) · Oncogene · doi:10.1038/sj.onc.1208932 · Cited by 46
HIPK2 overexpression leads to stabilization of p53 protein and increased p53 transcriptional activity by decreasing Mdm2 protein levels
Wang, Y., Debatin, K., & Hug, H. (2001) · BMC Molecular Biology · doi:10.1186/1471-2199-2-8 · Cited by 44
Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143.
Li, Y., Raffo, A. J., Drew, L., Mao, Y., Tran, A., Petrylak, D. P., & Fine, R. L. (2003) · PubMed · Cited by 43
Solution Structure of the p53 Regulatory Domain of the p19Arf Tumor Suppressor Protein
DiGiammarino, E. L., Filippov, I. V., Weber, J. D., Bothner, B. B., & Kriwacki, R. W. (2001) · Biochemistry · doi:10.1021/bi0024005 · Cited by 44
Grail as a molecular determinant for the functions of the tumor suppressor p53 in tumorigenesis
Chen, Y.-C., Chan, J. Y., Chiu, Y.-L., Liu, S. T., Lozano, G., Wang, S. L., Ho, C.-L., & Huang, S.-M. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.1 · Cited by 42
Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma
Patel, H., Polanco-Echeverry, G. M., Segditsas, S., Volikos, E., Reed, A. E. M., Lai, C. S. L., Guenther, T., Zaitoun, A. M., Sieber, O. M., Ilyas, M., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.23028 · Cited by 42
Polo-like kinases and DNA damage checkpoint: beyond the traditional mitotic functions
Bahassi, E. M. (2011) · Experimental Biology and Medicine · doi:10.1258/ebm.2011.011011 · Cited by 42
MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytes
Mayr, C., Bund, D., Schlee, M., Bamberger, M., Kofler, D. M., Hallek, M. J., & Wendtner, C. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2005.09.016 · Cited by 42
Copper uptake is required for pyrrolidine dithiocarbamate-mediated oxidation and protein level increase of p53 in cells
Furuta, S., ORTIZ, F., Sun, X. Z., Wu, H., Mason, A. Z., & Momand, J. A. (2002) · Biochemical Journal · doi:10.1042/bj20011251 · Cited by 42
Self-citation
Effects of theMDM2promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk
Knappskog, S., & Lønning, P. E. (2011) · Transcription · doi:10.4161/trns.2.5.16813 · Cited by 40
Modulation of the p53-MDM2 Interaction by Phosphorylation of Thr18: A Computational Study
Lee, H. J., Srinivasan, D., Coomber, D., Lane, D. P., & Verma, C. S. (2007) · Cell Cycle · doi:10.4161/cc.6.21.4923 · Cited by 41
Immunohistochemical study of p53-associated proteins in rat brain following lithium–pilocarpine status epilepticus
Tan, Z., Sankar, R., Tu, W., Shin, D. H., Liu, H., Wasterlain, C. G., & Schreiber, S. S. (2002) · Brain Research · doi:10.1016/s0006-8993(01)03360-1 · Cited by 41
Mdm2 Promotes Odontoblast-like Differentiation by Ubiquitinating Dlx3 and p53
Zheng, H., Yang, G., Fu, J., Chen, Z., & Yuan, G. (2019) · Journal of Dental Research · doi:10.1177/0022034519893672 · Cited by 40
A Novel Nuclear Interactor of ARF and MDM2 (NIAM) That Maintains Chromosomal Stability
Tompkins, V. S., Hagen, J., Frazier, A. A., Lushnikova, T., Fitzgerald, M. P., Tommaso, A. D., Ladevèze, V., Domann, F. E., Eischen, C. M., & Quelle, D. E. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m609612200 · Cited by 40
Regulation of Apoptosis During Mammary Involution by the p53 Tumor Suppressor Gene
Jerry, D. J., Dickinson, E. S., Roberts, A. L., & Said, T. K. (2002) · Journal of Dairy Science · doi:10.3168/jds.s0022-0302(02)74171-4 · Cited by 40
DNA-Encoded Macrocyclic Peptide Libraries Enable the Discovery of a Neutral MDM2–p53 Inhibitor
Silvestri, A. P., Zhang, Q., Ping, Y., Muir, E. W., Zhao, J., Chakka, S. K., Wang, G., Bray, W. M., Chen, W., Fribourgh, J. L., et al. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00117 · Cited by 39
Conformational changes of the p53‐binding cleft of MDM2 revealed by molecular dynamics simulations
Espinoza-Fonseca, M., & Trujillo-Ferrara, J. G. (2006) · Biopolymers · doi:10.1002/bip.20566 · Cited by 40
MDM2promoter SNP285 and SNP309; phylogeny and impact on cancer risk
Knappskog, S., & Lønning, P. E. (2011) · Oncotarget · doi:10.18632/oncotarget.243 · Cited by 39
Novel Insights into the Molecular Mechanisms Governing Mdm2 Ubiquitination and Destruction
Inuzuka, H., Fukushima, H., Shaik, S., & Wei, W. (2010) · Oncotarget · doi:10.18632/oncotarget.202 · Cited by 39
The unexplained survival of cells in oral cancer: what is the role of p53?
Whyte, D. A., Broton, C. E., & Shillitoe, E. J. (2002) · Journal of Oral Pathology and Medicine · doi:10.1034/j.1600-0714.2002._310301.x · Cited by 39
MDM4 (MDMX) Overexpression Enhances Stabilization of Stress-induced p53 and Promotes Apoptosis
Mancini, F., Gentiletti, F., D'Angelo, M., Giglio, S., Nanni, S., D’Angelo, C., Farsetti, A., Citro, G., Sacchi, A., Pontecorvi, A., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311793200 · Cited by 38
Somatostatin Receptor 1, a novel EBV-associated CpG hypermethylated gene, contributes to the pathogenesis of EBV-associated gastric cancer
Zhao, J., Liang, Q., Cheung, K.-F., Kang, W., Dong, Y., Lung, R. W. M., TONG, J. H. M., To, K., Sung, J. J. �., & Yu, J. Q. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.263 · Cited by 38
HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas
Sosin, A. M., Burger, A. M., Siddiqi, A., Abrams, J., Mohammad, R. M., & Al-Katib, A. M. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-57 · Cited by 40
S100 proteins interact with the N‐terminal domain of MDM2
van Dieck, J., Lum, J. K., Teufel, D. P., & Fersht, A. R. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.06.024 · Cited by 38
Protein Interface Pharmacophore Mapping Tools for Small Molecule Protein: Protein Interaction Inhibitor Discovery
Voet, A. R. D., Banwell, E. F., Sahu, K. K., Heddle, J. G., & Zhang, K. Y. J. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026611313090003 · Cited by 41
Isozyme-Specific Abnormalities of PKC in Thyroid Cancer: Evidence for Post-Transcriptional Changes in PKC Epsilon
Knauf, J. A., Ward, L. S., Nikiforov, Y. E., Nikiforova, M. N., Puxeddu, E., Medvedovic, M., Liron, T., Mochly‐Rosen, D., & Fagin, J. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.5.8441 · Cited by 38
Therapeutic inhibition of the MDM2-p53 interaction prevents recurrence of adenoid cystic carcinomas
Nör, F., Warner, K. A., Zhang, Z., Acasigua, G. A., Pearson, A. T., Kerk, S. A., Helman, J. I., Sant'Ana Filho, M., Wang, S., & Nör, J. E. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1235 · Cited by 37
Single-nucleotide polymorphisms p53 G72C and Mdm2 T309G in patients with psoriasis, psoriatic arthritis, and SAPHO syndrome
Assmann, G., Wagner, A. D., Monika, M., Pfoehler, C., Pfreundschuh, M. G., Tilgen, W., & Roemer, K. (2009) · Rheumatology International · doi:10.1007/s00296-009-1136-8 · Cited by 37
On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: A Brownian dynamics study
ElSawy, K. M., Verma, C. S., Joseph, T. L., Lane, D. P., Twarock, R., & Caves, L. S. D. (2013) · Cell Cycle · doi:10.4161/cc.23511 · Cited by 37
Tumor Suppressor SMAR1 Activates and Stabilizes p53 through Its Arginine-Serine-rich Motif
Jalota, A., Singh, K., Chavali, P. L., Kaul-Ghanekar, R., Jameel, S., & Chattopadhyay, S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413200200 · Cited by 37
Retracted
New thiazole carboxamides as potent inhibitors of Akt kinases
Chang, S., Zhang, Z., Zhuang, X., Luo, J., Cao, X., Li, H., Tu, Z., Lu, X., Ren, X., & Ding, K. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.11.080 · Cited by 37
The p53-Mdm2 Loop: A Critical Juncture of Stress Response
Levav-Cohen, Y., Goldberg, Z., Tan, K. H., Alsheich-Bartok, O., Zuckerman, V., Haupt, S., & Haupt, Y. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_9 · Cited by 38
Emergence of Members of TRAF and DUB of Ubiquitin Proteasome System in the Regulation of Hypertrophic Cardiomyopathy
Gupta, I., Varshney, N. K., & Khan, S. M. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00336 · Cited by 34
Harmonic Oscillations in Homeostatic Controllers: Dynamics of the p53 Regulatory System
Jolma, I. W., Ni, X. Y., Rensing, L., & Ruoff, P. (2010) · Biophysical Journal · doi:10.1016/j.bpj.2009.11.013 · Cited by 35
Characterization of murine gammaherpesvirus 68 v-cyclin interactions with cellular cdks
Upton, J. W., van Dyk, L. F., & Speck, S. H. (2005) · Virology · doi:10.1016/j.virol.2005.07.014 · Cited by 35
Expression, interaction, and proteolysis of death‐associated protein kinase and p53 within vulnerable and resistant hippocampal subfields following seizures
Araki, T., Shinoda, S., Schindler, C. K., Quan‐Lan, J., Meller, R., Taki, W., Simon, R. P., & Henshall, D. C. (2004) · Hippocampus · doi:10.1002/hipo.10184 · Cited by 34
Expression of Ku86 confers favorable outcome of tonsillar carcinoma treated with radiotherapy
Friesland, S., Kanter‐Lewensohn, L. R., Tell, R., Munck‐Wikland, E., Lewensohn, R., & Nilsson, A. (2002) · Head & Neck · doi:10.1002/hed.10199 · Cited by 34
Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers
Hata, A. N., Rowley, S. C., Archibald, H. L., Gomez‐Caraballo, M., Siddiqui, F. M., Ji, F., Jung, J., Light, M. E., Lee, J. S., Debüssche, L., et al. (2017) · Oncogene · doi:10.1038/onc.2017.258 · Cited by 35
MDM2 expression in EBV-infected nasopharyngeal carcinoma cells
Wu, H., Lu, T., Lee, J.-J., Hwang, J.-K., Lin, Y., Wang, C.-K., & Lin, C. (2004) · Laboratory Investigation · doi:10.1038/labinvest.3700183 · Cited by 34
Self-citation
Boosting p53 with interferon and viruses
Vilček, J. (2003) · Nature Immunology · doi:10.1038/ni0903-825 · Cited by 35
Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development
Eischen, C. M., Alt, J. R., & Wang, P. (2004) · Oncogene · doi:10.1038/sj.onc.1208052 · Cited by 32
The role of MDM2 in the proliferative activity of ameloblastoma
Sandra, F., Nakamura, N., Kanematsu, T., Hirata, M., & Ohishi, M. (2002) · Oral Oncology · doi:10.1016/s1368-8375(01)00036-7 · Cited by 33
Long isoform of ErbB3 binding protein, p48, mediates protein kinase B/Akt-dependent HDM2 stabilization and nuclear localization
Kim, C. K., Lee, S. B., Nguyen, T. L. X., Lee, K.-H., Um, S. H., Kim, J., & Ahn, J. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.08.013 · Cited by 32
Acaricidal Mechanism of Scopoletin Against Tetranychus cinnabarinus
Zhou, H., Zhang, Y., Lai, T. F., Liu, X., Guo, F.-Y., Guo, T., & Ding, W. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00164 · Cited by 32
Prospects for p53-based cancer therapy.
Stokłosa, T., & Gołąb, J. (2005) · Acta Biochimica Polonica · doi:10.18388/abp.2005_3445 · Cited by 32
Polo‐like kinase 1 regulates mitotic arrest after UV irradiation through dephosphorylation of p53 and inducing p53 degradation
Chen, J., Dai, G., Wang, Y., Wang, S., Pan, F., Xue, B., Zhao, D., & Li, C. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.05.047 · Cited by 32
Mathematical modelling of p53 basal dynamics and DNA damage response
Chong, K. H., Samarasinghe, S., & Kulasiri, D. (2014) · Mathematical Biosciences · doi:10.1016/j.mbs.2014.10.010 · Cited by 30
Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments
Suarez‐Kelly, L. P., Baldi, G. G., & Gronchi, A. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1618271 · Cited by 31
Regulation of p53 stabilization by DNA damage and protein kinase C.
Johnson, C., Lu, D., Huang, J., & Basu, A. (2002) · PubMed · Cited by 31
SMAR1-derived P44 Peptide Retains Its Tumor Suppressor Function through Modulation of p53
Jalota‐Badhwar, A., Kaul-Ghanekar, R., Mogare, D., Boppana, R., Paknikar, K. M., & Chattopadhyay, S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608434200 · Cited by 30
Molecular Imaging of MDM2 Messenger RNA with 99mTc-Labeled Antisense Oligonucleotides in Experimental Human Breast Cancer Xenografts
Fu, P., Shen, B., Zhao, C., & Tian, G. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.077982 · Cited by 30
Setting the stage for transformation: HTLV-1 Tax inhibition of p53 function
Cynthia, A. P.-M. (2005) · Frontiers in bioscience · doi:10.2741/1586 · Cited by 30
Clinorotation-induced autophagy via HDM2-p53-mTOR pathway enhances cell migration in vascular endothelial cells
Li, C., Sun, J., Gao, Y., Shi, F., Pan, Y., Wang, Y., & Sun, X. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0185-2 · Cited by 29
Master regulator genes and their impact on major diseases
Cai, W., Zhou, W., Han, Z., Lei, J., Zhuang, J., Zhu, P., Wu, X., & Yuan, W. (2020) · PeerJ · doi:10.7717/peerj.9952 · Cited by 31
Lack of p53 induction in fish cells by model chemotherapeutics
Embry, M. R., Billiard, S. M., & Giulio, R. T. D. (2006) · Oncogene · doi:10.1038/sj.onc.1209238 · Cited by 29
Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma
Ternovoi, V. V., Curiel, D. T., Smith, B. F., & Siegal, G. P. (2006) · Laboratory Investigation · doi:10.1038/labinvest.3700444 · Cited by 29
Novel radiosensitizing anticancer therapeutics.
Linkous, A. G., & Yazlovitskaya, E. M. (2012) · PubMed · Cited by 28
Profiling of differentially expressed apoptosis-related genes by cDNA arrays in human cord blood CD34+ cells treated with etoposide
Tao, W., Hangoc, G., Hawes, J. W., Si, Y. C., Cooper, S. H., & Broxmeyer, H. E. (2003) · Experimental Hematology · doi:10.1016/s0301-472x(02)01083-4 · Cited by 29
Loss of Heterozygosity Predicts Poor Survival After Resection of Pancreatic Adenocarcinoma
Franko, J., Krasinskas, A. M., Nikiforova, M. N., Zărnescu, N. O., Lee, K. K. W., Hughes, S. J., Bartlett, D. L., Zeh, H. J., & Moser, A. J. (2008) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-008-0577-9 · Cited by 29
Ribosomal protein S3 selectively affects colon cancer growth by modulating the levels of p53 and lactate dehydrogenase
Alam, E., Maaliki, L., & Nasr, Z. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05683-1 · Cited by 29
Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment
Hoffman-Luca, C. G., Yang, C.-Y., Lü, J., Ziazadeh, D. R., McEachern, D., Debüssche, L., & Wang, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128807 · Cited by 29
Efficacy of MDM2 inhibitor MI-219 against lung cancer cells alone or in combination with MDM2 knockdown, a XIAP inhibitor or etoposide.
Zheng, M., Yang, J., Xu, X., Sebolt, J. T., Wang, S., & Sun, Y. (2010) · PubMed · Cited by 28
Evaluation of transcriptional activity of p53 in individual living mammalian cells
Imagawa, T., Terai, T., Yamada, Y., Kamada, R., & Sakaguchi, K. (2009) · Analytical Biochemistry · doi:10.1016/j.ab.2009.01.030 · Cited by 28
A general synthesis of dirhodium metallopeptides as MDM2 ligands
Zaykov, A. N., & Ball, Z. T. (2011) · Chemical Communications · doi:10.1039/c1cc13169a · Cited by 27
Synthesis, Biological Evaluation, and In Silico Studies of Novel Aminated Xanthones as Potential p53-Activating Agents
Lemos, A., Gomes, A. S., Loureiro, J. B., Brandão, P., Palmeira, A., Pinto, M. M. M., Saraiva, L., & Sousa, E. (2019) · Molecules · doi:10.3390/molecules24101975 · Cited by 27
Therapeutic Strategies to Activate p53
Aguilar, A., & Wang, S. (2022) · Pharmaceuticals · doi:10.3390/ph16010024 · Cited by 28

Authors: Momand, J., Wu, H.-H., & Dasgupta, G.
Affiliations: California State University Los Angeles (US)
Corresponding author: Momand, Jamil
ORCID: Momand, Jamil
Wu, Hsiao-Huei
Venue: Gene
Publisher: Elsevier BV
Published: 2000-01
Volume: 242
Issue: 1-2
Pages: 15-29
ISSN: 0378-1119 (ISSN-L)
DOI: 10.1016/s0378-1119(99)00487-4
OpenAlex: W1973821009
Cited by: 641
References: 144
Citations by year: 2026: 6 · 2025: 11 · 2024: 17 · 2023: 19 · 2022: 24 · 2021: 10 · 2020: 17 · 2019: 16 · 2018: 22 · 2017: 14 · 2016: 17 · 2015: 31 · 2014: 21 · 2013: 21 · 2012: 24
FWCI: 4.03
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Gene (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Keywords: MDM2, p53, tumor suppressor regulation, MDMX, conserved domains, p53 ubiquitination, proteasomal degradation, cell cycle arrest, apoptosis, oncogenes, cancer therapy
MeSH terms: Amino Acid Sequence, Animals, Gene Expression Regulation, Humans, Models, Biological, Molecular Sequence Data, Nuclear Proteins, Proto-Oncogene Proteins, Genes, Tumor Suppressor, Tumor Suppressor Protein p53, Sequence Homology, Amino Acid, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

MDM2 — master regulator of the p53 tumor suppressor protein

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks